Skip to main content
. 2020 Dec 29;13(2):e11902. doi: 10.15252/emmm.201911902

Figure 6. Antitumor activity of the Fabsc and IgGsc molecules in immunodeficient mice.

Figure 6

  • A
    4 × 106 LNCaP cells were injected into NSG mice (five per group) followed 1 day later by transfer of human PBMC (107 i.p.) and application of bsAbs (10 µg) at day 1 and 4 (IgGsc) and daily at day 1–6 (Fabsc), respectively. At day 21, mice were killed and tumor cells in the lung were quantified by flow cytometry after enzymatic digestion. Statistical analysis was performed using the unpaired t‐test. Error bars represent standard deviation of the mean value.
  • B, C
    106 LNCaP cells were injected s.c. into the right flank of NSG mice (five per group), and treatment with PBMC and bsAbs was started when tumors had reached a diameter of 5 mm. BsAbs (2 µg per dose) were applied at day 1, 8, and 15 (IgGsc) and daily at day 1–3, day 8–10, and day 15–17 (Fabsc), PBMC was applied at day 1, 8, and 15. Mean values and standard deviations of five mice per group are indicated.